Literature DB >> 25618339

Protocols for the routine screening of drug sensitivity in the human parasite Trichomonas vaginalis.

Manal J Natto1, Anthonius A Eze, Harry P de Koning.   

Abstract

Trichomonas vaginalis is a sexually transmitted protozoan parasite of humans. Treatment of trichomoniasis is almost completely dependent on the old drug metronidazole and is hampered by resistance. New drug development, like routine screening for drug resistance, has however been hampered by the lack of reliable screening protocols with sufficient throughput. Here we report on two separate in vitro protocols that use fluorescent dyes and allow for standardized drug sensitivity testing on the required scale.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25618339     DOI: 10.1007/978-1-4939-2269-7_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Comprehensive characterization of purine and pyrimidine transport activities in Trichomonas vaginalis and functional cloning of a trichomonad nucleoside transporter.

Authors:  Manal J Natto; Yukiko Miyamoto; Jane C Munday; Tahani A AlSiari; Mohammed I Al-Salabi; Neils B Quashie; Anthonius A Eze; Lars Eckmann; Harry P De Koning
Journal:  Mol Microbiol       Date:  2021-11-20       Impact factor: 3.501

2.  Deazapurine Nucleoside Analogues for the Treatment of Trichomonas vaginalis.

Authors:  Manal J Natto; Fabian Hulpia; Eric R Kalkman; Susan Baillie; Amani Alhejeli; Yukiko Miyamoto; Lars Eckmann; Serge Van Calenbergh; Harry P de Koning
Journal:  ACS Infect Dis       Date:  2021-05-11       Impact factor: 5.578

3.  Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents.

Authors:  Anastasia L Khandazhinskaya; Elena S Matyugina; Pavel N Solyev; Maggie Wilkinson; Karen W Buckheit; Robert W Buckheit; Larisa N Chernousova; Tatiana G Smirnova; Sofya N Andreevskaya; Khalid J Alzahrani; Manal J Natto; Sergey N Kochetkov; Harry P de Koning; Katherine L Seley-Radtke
Journal:  Molecules       Date:  2019-09-21       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.